Furthermore, subsequent meta-analyses with a focus on adverse events have confirmed that febrile neutropenia and related infections are low (1% and 3%, respectively) in patients receiving CDK4/6 inhibitors38. The gene discussed is CDK4; the disease is neutropenia.